Schedule 13G ownership disclosure
Apellis Pharmaceuticals Inc
Security class unavailable · CUSIP: 03753U106
Event date: 2017-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 11,353,303
- Percent of class
- 22.6000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-18-009120
- Form type
- SC 13G
- Filer
- Apellis Pharmaceuticals, Inc.
- CIK
- CIK 1492422
- Filed
- Feb 14, 2018
- Reporting period
- Dec 31, 2017
- Description
- Schedule 13G beneficial ownership